Skip to main content
. 2020 Dec 14;2020:6685043. doi: 10.1155/2020/6685043

Figure 2.

Figure 2

Effects of allicin on the human NP cell viability and proliferation. (a) The human NP cells were treated with allicin (0, 5, 10, 20, and 40 μM) for 24 h, and 0 μM group served as a control. The cell viability of each group was detected by a CCK-8 assay. ∗p < 0.05 versus the control group, n = 3. (b) The human NP cells were treated with allicin (0-40 μM) for 24 h, and 0 μM group served as a control. The cell proliferation was determined using EdU staining combined with DAPI staining for the nuclei under fluorescence microscope, with the EdU positive cells quantitated. Original magnification: ×200. ∗p < 0.05 versus the control group, n = 3. (c) The human NP cells pretreated by allicin (0, 5, 10, and 20 μM) were treated with 400 μg/ml AOPP, and the cell viability of each group was examined by the CCK-8 assay. #p < 0.05 versus the control group, ∗p < 0.05 versus the AOPP alone treatment group, n = 3. (d) The cell proliferation of each group was determined using EdU staining under fluorescence microscope, with the EdU positive cells quantitated. Original magnification: ×200. Data were represented as mean ± SD. ##p < 0.01 versus the control group, ∗p < 0.05 versus the AOPP alone treatment group, n = 3.